| Li, Yan |
NCT04035824: Gastrodia and Uncaria Recipe in Treating Stage-one Hypertension: an Evidence-based Optimization Study |
|
|
| Completed | 4 | 605 | RoW | Gastrodia and Uncaria granule, Placebo of Gastrodia and Uncaria granule | Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Hypertension | 04/24 | 04/24 | | |
NCT05089448: Morning Versus Bedtime Dosing of Antihypertensive Medication |
|
|
| Recruiting | 4 | 300 | RoW | Alisartan, Amlodipine besylate | Yan Li | Hypertension, Blood Pressure, Drug Use | 06/26 | 09/26 | | |
NCT03825692: International Clinical Study of Zhizhu Kuanzhong Capsule |
|
|
| Recruiting | 4 | 480 | RoW | Zhizhu Kuanzhong Capsule, ZZKZ capsule, Zhizhu Kuanzhong Placebo Capsule, placebo | Xiyuan Hospital of China Academy of Chinese Medical Sciences | Functional Dyspepsia, Postprandial Distress Syndrome | 12/23 | 12/23 | | |
| Completed | 3 | 1177 | Europe, Canada, Japan, US, RoW | Mirikizumab SC, LY3074828, Mirikizumab IV, Placebo SC | Eli Lilly and Company | Ulcerative Colitis | 11/21 | 12/24 | | |
|
|
NCT04078568: Efficacy of Immunoglobulin Plus Prednisolone in Reducing Coronary Artery Lesion in Patients With Kawasaki Disease |
|
|
| Active, not recruiting | 3 | 3208 | RoW | IVIG, Intravenous Immunoglobulins, Human, Aspirin, Acetylsalicylic acid, Prednisolone, STEROLONE | Children's Hospital of Fudan University, Jiangxi Province Children's Hospital, First People's Hospital of Hangzhou, Shengjing Hospital, The First Hospital of Jilin University, Chengdu Women's and Children's Central Hospital, Children's Hospital of Chongqing Medical University, Inner Mongolia People's Hospital, Sichuan Provincial People's Hospital, Wuhan Union Hospital, China, Third Affiliated Hospital of Zhengzhou University, Children's Hospital of Soochow University, Yuying Children's Hospital of Wenzhou Medical University, Beijing Children's Hospital, Qilu Hospital of Shandong University | Kawasaki Disease | 12/24 | 12/25 | | |
| Active, not recruiting | 3 | 404 | Europe, Canada, Japan, US, RoW | Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627, Placebo | Chinook Therapeutics, Inc. | IgA Nephropathy, Immunoglobulin A Nephropathy | 12/26 | 12/26 | | |
NCT05433480: A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer |
|
|
| Active, not recruiting | 3 | 274 | RoW | BPI-16350, placebo, Fulvestrant | Betta Pharmaceuticals Co., Ltd. | Breast Cancer | 12/23 | 07/25 | | |
nAMD, NCT05461339: TAB014 Compared to Lucentis® in Patients with Neovascular Age-related Macular Degeneration |
|
|
| Active, not recruiting | 3 | 488 | RoW | TAB014 Monoclonal Antibody Injection, TAB014, Ranibizumab Injection [Lucentis], Lucentis | TOT Biopharm Co., Ltd., Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. | Neovascular Age-related Macular Degeneration | 09/24 | 02/25 | | |
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) |
|
|
| Recruiting | 3 | 12500 | Europe, Canada, Japan, US, RoW | Lepodisiran Sodium, LY3819469, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a) | 03/29 | 03/29 | | |
QWINT-2, NCT05362058: A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time |
|
|
| Completed | 3 | 928 | Europe, Canada, Japan, US, RoW | Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Degludec | Eli Lilly and Company | Diabetes, Type 2 Diabetes | 04/24 | 04/24 | | |
TRAPP, NCT05811676: Tranexamic Acid for the Prevention of Postpartum Hemorrhage in Pregnant Women with Placenta Previa |
|
|
| Recruiting | 3 | 1680 | RoW | Tranexamic acid, 0.9% sodium chloride | Guangzhou Medical University, Dongguan Maternal and Child Health Care Hospital, Foshan Women and Children Hospital, BoAi Hospital of Zhongshan, Women and Children's Hospital of Chongqing Medical University, Tianjin Central Hospital of Gynecology Obstetrics, Shandong Provincial Maternal and Child Health Care Hospital Affiliated to Qingdao University, Jinan, Urumqi Maternal and Child Health Care Hospital, Zhuhai Women and Children's Hospital, The First Affiliated Hospital of Zhengzhou University, Hunan Provincial Maternal and Child Health Care Hospital, Dalian women and children's medical group, Nanfang Hospital, Southern Medical University, Huadu District People's Hospital of Guangzhou, Northwest Women's and Children's Hospital, Xi'an, Shaanxi, First Affiliated Hospital, Sun Yat-Sen University, Shenzhen Maternity & Child Healthcare Hospital, Shenzhen Baoan Women's and Children's Hospital, Dongguan People's Hospital, First Affiliated Hospital of Xinjiang Medical University, Tongji Hospital, Peking Union Medical College, Peking University First Hospital, The First Affiliated Hospital of Guangzhou Medical University, Second Affiliated Hospital of Guangzhou Medical University, Fifth Affiliated Hospital of Guangzhou Medical University, Shijiazhuang Obstetrics and Gynecology Hospital | Hemorrhage, Postpartum, Placenta Previa | 02/25 | 04/25 | | |
NCT04578613: ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL |
|
|
| Recruiting | 3 | 218 | RoW | ICP-022, Chlorambucil, Rituximab | Beijing InnoCare Pharma Tech Co., Ltd. | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 12/24 | 06/25 | | |
| Active, not recruiting | 3 | 15374 | Europe, Canada, Japan, US, RoW | Tirzepatide, LY3298176, Placebo | Eli Lilly and Company | Obesity, Overweight | 10/27 | 10/27 | | |
NCT06083623: A Trial to Evaluate the Efficacy and Safety of TNM001 for the Prevention of Lower Respiratory Tract Infection Caused by Respiratory Syncytial Virus in Infants |
|
|
| Not yet recruiting | 2b | 2250 | RoW | TNM001, placebo | Zhuhai Trinomab Pharmaceutical Co., Ltd. | Respiratory Syncytial Virus Infections | 05/26 | 08/26 | | |
NCT04405154: A Study of Concomitant Camrelizumab With Chemoradiation for Locally Advanced Head and Neck Cancer |
|
|
| Not yet recruiting | 2 | 32 | NA | Camrelizumab, SHR-1210, Cisplatin, Platinol, IMRT or VMAT | West China Hospital | Head and Neck Neoplasms | 05/23 | 05/25 | | |
NCT05299697: A Study of TG103 Injection in Overweight or Obesity |
|
|
| Recruiting | 2 | 195 | RoW | TG103 15 mg, TG103 22.5 mg, Placebo | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | Overweight or Obesity | 06/23 | 09/23 | | |
NCT06206720: A Study of Deuremidevir Hydrobromide for Suspension in Chinese Infants Hospitalized With RSV |
|
|
| Recruiting | 2 | 60 | RoW | Deuremidevir Hydrobromide for Suspension, VV116, Placebo, VV116 placebo | Vigonvita Life Sciences | Respiratory Syncytial Virus Infection | 01/25 | 01/25 | | |
NCT06481085: To Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus |
|
|
| Not yet recruiting | 2 | 318 | RoW | HDM1002 50 mg, HDM1002, HDM1002 100 mg, HDM1002 200 mg, HDM1002 400 mg, HDM1002 200 mg BID, Placebo, Matching placebo for group A to group E | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Type 2 Diabetes | 04/25 | 04/25 | | |
| Active, not recruiting | 2 | 103 | Europe, US, RoW | Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627 | Novartis Pharmaceuticals | IgA Nephropathy, Focal Segmental Glomerulosclerosis, Alport Syndrome, Diabetic Kidney Disease, Diabetic Nephropathy Type 2, Immunoglobulin A Nephropathy | 07/24 | 07/26 | | |
SKB264-II-04, NCT05816252: A Study of SKB264 for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) |
|
|
| Recruiting | 2 | 498 | Europe, RoW | SKB264, MK-2870, Pembrolizumab, MK-3475, Carboplatin, Carboplatin for injection, Osimertinib, Osimertinib Mesylate | Klus Pharma Inc., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Non-small Cell Lung Cancer | 12/25 | 10/26 | | |
NCT05879055: A Study of PM8002 in Combination With Chemotherapy in Patients With NEN |
|
|
| Recruiting | 2 | 60 | RoW | PM8002, FOLFIRI | Biotheus Inc. | Neuroendocrine Neoplasm | 01/27 | 01/28 | | |
NCT06106841: TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL) |
|
|
| Recruiting | 1/2 | 39 | RoW | 400mg of TQB3909 tablets, 600mg of TQB3909 tablets | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Mantle Cell Lymphoma | 12/24 | 12/24 | | |
NCT06052813: A Study of BN104 in the Treatment of Acute Leukemia |
|
|
| Recruiting | 1/2 | 90 | RoW | BN104 | BioNova Pharmaceuticals (Shanghai) LTD. | ALL, Adult, AML, Adult | 06/26 | 06/27 | | |
NCT05056389: Normothermic Intraperitoneal Chemotherapy - Long Term in Peritoneal Metastases From Colorectal Cancer (NIPEC-OXA) |
|
|
| Recruiting | 1 | 20 | Europe | Oxaliplatin, Intraperitoneal catheter | Oslo University Hospital | Peritoneal Metastases, Colo-rectal Cancer | 03/23 | 06/23 | | |
| Recruiting | 1 | 76 | RoW | HS-10380, Placebo | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Schizophrenia | 06/23 | 07/23 | | |
NCT06594315: Assessing Brain Metabolism Using MRS With Deuterated Glucose |
|
|
| Active, not recruiting | N/A | 80 | US | Deuterated Glucose, Hydrogen gas (H2) glucose, [6,6'-2H2] glucose, Magnetic Resonance Imaging (MRI), MRI, Blood Sample, MR spectroscopy (MRS), MRS | University of California, San Francisco | Glioma | 07/27 | 07/27 | | |
NCT06610604: Health-Related Quality of Life and Emotions in Patients with Thyroid Nodules |
|
|
| Recruiting | N/A | 500 | RoW | thermal ablation, thyroidectomy | Ming-an Yu | Thyroid Nodule | 06/27 | 12/27 | | |
NCT05258461: An Innovative Smartphone Application for Adverse Event Management During Breast Cancer Adjuvant Chemotherapy |
|
|
| Not yet recruiting | N/A | 108 | NA | use of a smartphone app for adverse event management, conventional adverse event management | Peking Union Medical College Hospital | Breast Cancer | 10/22 | 12/22 | | |
NCT03547856: A Registry Study on the "Action of Controlling Ambulatory Blood Pressure to Target in Ten Thousand Patients" |
|
|
| Recruiting | N/A | 10000 | RoW | | Yan Li | Hypertension, Blood Pressure, Cardiovascular Diseases | 09/26 | 12/26 | | |
ASORPWICE, NCT03521739: Association of Synchronous Four-limb blOod pRessure and Pulse Wave velocIty With Cardiovascular Events |
|
|
| Recruiting | N/A | 100000 | RoW | | Chinese Academy of Medical Sciences, Fuwai Hospital | Blood Pressure, Pulse Wave Analysis, Ankle Brachial Index, Patient Outcome Assessment | 12/22 | 12/23 | | |
| Recruiting | N/A | 4500 | RoW | | Shanghai Institute of Hypertension | Nocturnal Hypertension | 09/26 | 12/26 | | |
PROMISE, NCT04135911: A Prospective Study on The"Management of Hypertension in Young and Middle-aged Subjects in Enterprises Setting" |
|
|
| Suspended | N/A | 2000 | RoW | | Yan Li | Hypertension, Blood Pressure | 03/26 | 03/26 | | |
NCT05535400: Effects of Physical-Psychological Integrative Intervention on SCI Patient: a Pilot Randomized Controlled Trial |
|
|
| Completed | N/A | 72 | RoW | Physical-Psychological Integrative Intervention, Brief online didactic education | The Hong Kong Polytechnic University | Spinal Cord Injuries, Physical Inactivity, Depression, Chronic Pain | 12/22 | 07/23 | | |
| Recruiting | N/A | 60 | US | | Oregon Health and Science University, National Eye Institute (NEI) | Fuchs Dystrophy, Pseudophakic Bullous Keratopathy | 06/26 | 06/26 | | |
NCT05558657: Effect of Acupressure on Constipation in Community-dwelling Spinal Cord Injury Patients: a Randomized Controlled Trial |
|
|
| Completed | N/A | 80 | RoW | Home-based, acupressure combined with nursing education, Home-based, manual light touch of the abdomen combined with nursing education | The Hong Kong Polytechnic University | Spinal Cord Injuries, Traditional Chinese Medicine | 09/24 | 09/24 | | |
NCT05531058: The Impact of a Web-based Psychoeducation Programme With a Motivational AI Chatbot on Covid-19 Vaccine Hesitancy |
|
|
| Completed | N/A | 168 | RoW | AI-driven Vaccine Communicator, Self-learning of COVID-19 vaccine knowledge | The Hong Kong Polytechnic University | Vaccine Hesitancy, COVID-19 | 06/24 | 06/24 | | |
NCT01243931: Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy |
|
|
| Recruiting | N/A | 80 | US | OCT-guided laser phototherapeutic keratectomy, Manufacturer/Name OCT Technology 510(K), Optovue/RTVue-CAM Fourier-domain K071250, Bioptigen/Bioptigen Fourier-domain K063343, Zeiss/Visante Time-domain K051789 | Oregon Health and Science University, National Eye Institute (NEI) | Corneal Opacity | 12/26 | 12/26 | | |
NCT02109471: Observational Study of Corneal Opacities in Adults |
|
|
| Recruiting | N/A | 150 | US | | Oregon Health and Science University, National Eye Institute (NEI) | Corneal Opacities (Scar and Stromal Dystrophy) | 12/25 | 12/25 | | |
| Recruiting | N/A | 75 | US | | Oregon Health and Science University | Uveitis | 12/25 | 12/25 | | |
NCT06306378: The Relationship Between Social Memory Disorders and Sleep Spindles in Children With Autism Spectrum Disorder |
|
|
| Recruiting | N/A | 60 | RoW | social memory levels and spindle levels | First Affiliated Hospital Xi'an Jiaotong University, Xi'an TCM Hospital of Encephalopathy | Autism Spectrum Disorder | 03/24 | 04/24 | | |
| Recruiting | N/A | 445 | US | Optical Coherence Tomography | Oregon Health and Science University | Keratoconus, Corneal Opacity, Corneal Dystrophy | 04/25 | 04/26 | | |
| Active, not recruiting | N/A | 60 | US | SKY Breath Intervention | University of California, San Francisco | Depression, Anxiety Disorders | 04/25 | 12/25 | | |
OCT IOL, NCT00532051: Intraocular Lens Power Calculation After Laser Refractive Surgery Based on Optical Coherence Tomography |
|
|
| Recruiting | N/A | 690 | US | OCT measurements, Manufacturer/Name OCT Technology 510(K), Optovue/RTVue-CAM Fourier-domain K071250, Bioptigen/Bioptigen Fourier-domain K063343, Zeiss/Visante Time-domain K051789 | Oregon Health and Science University, National Eye Institute (NEI) | Cataract | 07/26 | 07/26 | | |
NCT06686134: Comprehensive Clinical Evaluation Study of GLP-1RA |
|
|
| Recruiting | N/A | 492 | RoW | | LI YAN | T2DM | 12/25 | 07/26 | | |
| Active, not recruiting | N/A | 482 | RoW | | Takeda | Multiple Myeloma, Neoplasms, Plasma Cell | 09/25 | 09/25 | | |
TEAS/ASD, NCT06763237: Abdominal Transcutaneous Electrical Acupoint Stimulation on Children With Autism Spectrum Disorder |
|
|
| Not yet recruiting | N/A | 42 | RoW | abdominal transcutaneous electrical acupoint stimulation (abdominal TEAS), TEAS, Applied Behavior Analysis (ABA) therapy | First Affiliated Hospital Xi'an Jiaotong University, Xian Children's Hospital | Autism Spectrum Disorder, Autism in Children | 01/26 | 01/26 | | |
NCT05282095: Effect of HPV Integration on Prognosis of Young Women With CIN2 in China |
|
|
| Recruiting | N/A | 300 | RoW | Follow up | Fujian Maternity and Child Health Hospital | Cervical Intraepithelial Neoplasia, HPV Infection, Virus Integration, HSIL, High Grade Squamous Intraepithelial Lesions | 12/25 | 05/26 | | |
| Recruiting | N/A | 300 | RoW | Diagnostic biomarker | Shixuan Wang | Uterine Sarcoma | 11/25 | 11/25 | | |
| Recruiting | N/A | 258 | US | | Oregon Health and Science University, National Eye Institute (NEI) | Keratoconus, Irregular; Contour of Cornea | 12/25 | 12/26 | | |
NCT04995159: Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVasâ„¢ BRS System |
|
|
| Not yet recruiting | N/A | 2150 | RoW | Single anti-platelet therapy, SAPT strategy, Dual anti-platelet therapy, DAPT strategy | Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Heart Disease | 01/26 | 01/28 | | |
| Recruiting | N/A | 287 | Europe | Surgical treatment, Non-surgical treatment | Kolding Sygehus, Copenhagen University Hospital, Hvidovre, Zealand University Hospital, Oslo University Hospital, Helse Stavanger HF, Sahlgrenska University Hospital, Sweden, Uppsala University Hospital, Odense University Hospital, Hospital of Southern Jutland, Slagelse Hospital, Aalborg University Hospital, University Hospital, Umeå, Nordsjaellands Hospital, Holbaek Sygehus, Aarhus University Hospital, Copenhagen University Hospital, Herlev-Gentofte, University Hospital Bispebjerg and Frederiksberg, Viborg Regional Hospital, Karolinska University Hospital, Danderyd Hospital, Tampere University Hospital, Helsinki University Central Hospital | Fracture Humerus of Shaft | 12/25 | 07/31 | | |
NCT05858944: Home Blood Pressure Intervention in the Community Trial |
|
|
| Recruiting | N/A | 10000 | RoW | Intensive Home BP control, Home BP<125/75 mmHg, Standard Home BP control, Home BP<135/85 mmHg | Shanghai Institute of Hypertension | Home Blood Pressure | 12/29 | 06/30 | | |
| Recruiting | N/A | 450 | RoW | Healthy control specimen collection, Non-Borrmann IV patient specimen collection, Borrmann IV patient specimen collection | First Hospital of China Medical University, Liaoning Cancer Hospital & Institute, The Second Hospital of Shandong University, The General Hospital of Fushun Mining Bureau, The fourth People's Hospital of Changzhou, The First People's Hospital of Jingzhou | Stomach Neoplasms, Gut Microbiota, Metabolomics | 01/24 | 12/25 | | |
| Recruiting | N/A | 500 | RoW | YISAIPU® ( An etanercept biosimilar), a recombinant tumor necrosis factor receptor-Fc fusion protein, rhTNFR:Fc, csDMARDs | The First Affiliated Hospital of Xiamen University | Rheumatoid Arthritis | 06/25 | 12/25 | | |
| Liu, Yang |
NCT05694585: Effect of Esmolol on Perioperative Stress Reaction |
|
|
| Not yet recruiting | 4 | 46 | NA | Esmolol, Esmolol hydrochloride, saline, 0.9% sodium chloride injection solution | Xiumei Song | Esmolol, Stress Reaction, Airway Obstruction, Catecholamine; Overproduction | 12/23 | 12/23 | | |
NCT03989336: A Study of the Pan-immunotherapy in Patients With Relapsed/Refractory Ovarian Cancer |
|
|
| Completed | 2 | 84 | RoW | Manganese Chloride, nab-paclitaxel, Paclitaxel For Injection (Albumin Bound), Platinum chemotherapy, Sintilimab, anti-PD-1 antibody; PD-1 inhibitor | Chinese PLA General Hospital | Ovarian Cancer | 05/22 | 12/23 | | |
NCT06404840: Evaluating Nimotuzumab in Combination With AG Regimen for Pancreatic Cancer With Liver Metastases : A Prospective, Single-Arm, Phase II Study |
|
|
| Recruiting | 2 | 30 | RoW | nimotuzumab, AG chemotherapy | Tianjin Medical University Cancer Institute and Hospital | Pancreatic Cancer | 03/25 | 05/26 | | |
NCT03250962: SHR-1210 Alone or in Combination With Decitabine in Relapsed or Refractory Hodgkin Lymphoma |
|
|
| Recruiting | 2 | 280 | RoW | SHR-1210, Decitabine | Chinese PLA General Hospital | Hodgkin Lymphoma | 07/22 | 03/25 | | |
NCT04514081: The Clinical Trial of Chidamide+Decitabine+Camrelizumab Versus Decitabine+Camrelizumab in Anti-PD-1 Antibody Resistant Patients With Classical Hodgkin Lymphoma. |
|
|
| Recruiting | 2 | 200 | RoW | Chidamide; Decitabine; Camrelizumab, Decitabine+Camrelizumab | Chinese PLA General Hospital | Hodgkin Lymphoma, Anti-PD-1 Antibody Resistant | 08/22 | 08/25 | | |
NCT06586697: First-line Treatment for ES-SCLC with Chemotherapy Combined with PD-1/PD-L1 Inhibitor Sequential Thoracic Radiotherapy |
|
|
| Recruiting | 2 | 47 | RoW | Thoracic Radiotherapy | Henan Cancer Hospital | Extensive-stage Small-cell Lung Cancer | 01/26 | 03/26 | | |
CHN-PLAGH-BT-045, NCT04233294: Addition of Chidamide to the Combination Treatment of Decitabine Plus Camrelizumab in Combination Treatment Resistant/Relapsed Patients With Classical Hodgkin Lymphoma |
|
|
| Recruiting | 2 | 100 | RoW | Chidamide, Camrelizumab, Decitabine | Chinese PLA General Hospital | Hodgkin Lymphoma | 02/24 | 02/26 | | |
NCT06375486: Ivonescimab Combined With HAIC for the Treatment of Unresectable Hepatocellular Carcinoma（uHCC）. |
|
|
| Recruiting | 2 | 30 | RoW | Ivonescimab（AK112，a PD-1/VEGF bispecific antibody）, HAIC | Tianjin Medical University Cancer Institute and Hospital | Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma | 03/25 | 06/26 | | |
OBU-HCC-II-001, NCT06405061: Evaluation of Effectiveness and Safety of HAIC in Combination With Adebrelimab and Bevacizumab for Potentially Resectable Hepatocellular Carcinoma |
|
|
| Recruiting | 2 | 40 | RoW | Adebrelimab, Bevacizumab, HAIC | Tianjin Medical University Cancer Institute and Hospital | Adebrelimab, Hepatocellular Carcinoma | 05/25 | 08/27 | | |
NCT06342466: Bortezomib, Pomalidomide, Dexamethasone for Systemic AL Amyloidosis |
|
|
| Recruiting | 2 | 40 | RoW | Bortezomib, Velcade, Pomalidomide, Dexamethasone | Jin Lu, MD | Systemic Amyloidosis | 12/26 | 12/26 | | |
NCT06418477: Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone Therapy for Patients with MIDD |
|
|
| Recruiting | 2 | 20 | RoW | Dara-CyBorD | Peking University People's Hospital | Monoclonal Gammopathy of Renal Significance | 12/25 | 12/26 | | |
NCT06558773: GSL Synthetase Inhibitor Plus Immune Checkpoint Inhibitor and/or Regorafenib in Previously Treated pMMR/MSS CRC. |
|
|
| Not yet recruiting | 2 | 120 | RoW | Eliglustat+Immune checkpoint inhibitor+Regorafenib, Regorafenib(Stivarga), Eliglustat(Cerdelga), Eliglustat+Immune checkpoint inhibitor, Regorafenib+Immune checkpoint inhibitor | Chinese PLA General Hospital | Colorectal Cancer | 08/26 | 08/27 | | |
NCT06606483: A Study to Evaluate the Efficacy and Safety of MDR-001 in Subjects Who Are Obesity or Overweight |
|
|
| Not yet recruiting | 2 | 300 | RoW | MDR-001, Placebo | MindRank AI Ltd | Obesity, Overweight and Obesity | 07/25 | 09/25 | | |
NCT03989310: An Open-label, Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic Pancreatic Cancer |
|
|
| Recruiting | 1/2 | 50 | RoW | Manganese Chloride, nab-paclitaxel, Paclitaxel For Injection (Albumin Bound), Gemcitabine, anti-PD-1 antibody, Anti-PD-1 monoclonal antibody; PD-1 inhibitor | Chinese PLA General Hospital | Pancreatic Cancer | 05/21 | 03/22 | | |
NCT04553393: Decitabine-primed Tandem CD19/CD20 CAR T Cells Plus Epigenetic Agents in Aggressive r/r B-NHL With Huge Tumor Burden |
|
|
| Recruiting | 1/2 | 80 | RoW | Chidamide, cohort 2, Decitabine, cohort 3, Chidamide and Decitabine, cohort 4, Decitabine-primed Tandem CAR19/20 engineered T cells, cohort 1 | Chinese PLA General Hospital | Refractory or Relapsed Aggressive r/r B-NHL With Huge Tumor Burden | 09/21 | 09/22 | | |
NCT04588324: Study of SHR2150 (TLR7 Agonist) in Combination With Chemotherapy Plus PD-1 or CD47 Antibody in Subjects With Unresectable/ Metastatic Solid Tumors |
|
|
| Recruiting | 1/2 | 50 | RoW | SHR2150, Anti-Cancer Agent | Chinese PLA General Hospital | Solid Tumor | 11/21 | 11/22 | | |
NCT04897477: Azacytidine, Bendamustine, Piamprizumab in Refractory/Relapsed B-cell Non-Hodgkin's Lymphoma |
|
|
| Recruiting | 1/2 | 30 | RoW | Azacytidine, Bendamustine and Piamprizumab | Chinese PLA General Hospital | Non-hodgkin Lymphoma,B Cell | 04/22 | 04/23 | | |
NCT04873440: An Open-label, Phase I/II Study of Manganese Plus Radiotherapy in Patients With Metastatic Solid Tumors or Lymphoma |
|
|
| Recruiting | 1/2 | 10 | RoW | Manganese Chloride, Mn2+, Radiotherapy, Chemo-immunotherapy | Chinese PLA General Hospital | Solid Tumor, Lymphoma | 05/22 | 05/23 | | |
NCT04697940: Decitabine-primed Tandem CD19/CD20 CAR T Cells Treatment in r/r B-NHL |
|
|
| Recruiting | 1/2 | 33 | RoW | Decitabine-primed Tandem CAR19/20 engineered T cells, Fludarabine, Fludarabine Phosphate for Injection, Cyclophosphamide, Cyclophosphamide for Injection | Han weidong | Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma, Decitabine-primed Tandem CD19/CD20 CAR T Cells | 12/24 | 12/25 | | |
NCT06321289: Allogeneic TRAC Locus-inserted CD19-targeting STAR T Cell Therapy in r/r B-NHL |
|
|
| Recruiting | 1/2 | 30 | RoW | Allogeneic CD19-STAR T cell, Allogeneic CD19-targeting synthetic T-cell receptor antigen receptor T cells, Fludarabine, Fludarabine Phosphate for Injection, Cyclophosphamide, Cyclophosphamide for Injection | Chinese PLA General Hospital | Non-hodgkin Lymphoma,B Cell | 03/26 | 03/27 | | |
NCT04337606: Chidamide in Combination With Decitabine in Non-Hodgkin's Lymphoma Relapsed After Chimeric Antigen Receptor |
|
|
| Recruiting | 1/2 | 100 | RoW | Chidamide, Decitabine, Camrelizumab | Chinese PLA General Hospital | Non Hodgkin Lymphoma | 04/24 | 04/26 | | |
NCT06323525: TCR Reserved and Power3 Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma |
|
|
| Recruiting | 1/2 | 30 | RoW | TCR reserved and Power3 gene knock-out allogeneic CD19-targeting CAR-T cell (ATHENA-2 CAR-T), Fludarabine, Fludarabine Phosphate for Injection, Cyclophosphamide, Cyclophosphamide for Injection | Chinese PLA General Hospital | Non-hodgkin Lymphoma | 04/26 | 04/27 | | |
NCT05631912: TRAC Locus-inserted CD19-targeting STAR-T Cell Therapy in r/r B-NHL |
|
|
| Recruiting | 1/2 | 38 | RoW | Autologous CD19-STAR-T cell, Autologous CD19-targeting synthetic T-cell receptor antigen receptor T cells, Fludarabine, Fludarabine Phosphate for Injection, Cyclophosphamide, Cyclophosphamide for Injection | Chinese PLA General Hospital | Non-hodgkin Lymphoma,B Cell | 12/24 | 12/25 | | |
NCT05554939: Allogenic CD19-targeting CAR-γδT Cell Therapy in r/r NHL |
|
|
| Recruiting | 1/2 | 30 | RoW | Allogenic CD19-CAR-γδT cell, Fludarabine, Fludarabine Phosphate for Injection, Cyclophosphamide, Cyclophosphamide for Injection | Chinese PLA General Hospital | Non Hodgkin's Lymphoma | 12/25 | 12/26 | | |
NCT06481735: TCR Reserved and Power3 Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL |
|
|
| Recruiting | 1/2 | 30 | RoW | TCR reserved and Power3 Gene Knock-out Allogeneic CD19-targeting CAR-T cell, Allogeneic Power3 knock-out CD19 CAR-T, Fludarabine, Fludarabine Phosphate for Injection, Cyclophosphamide, Cyclophosphamide for Injection | Chinese PLA General Hospital, Peking University | Acute Lymphocytic Leukemia | 02/27 | 02/28 | | |
NCT03381807: Human Amniotic Epithelial Stem Cell in Treatment of Refractory Severe Intrauterine Adhesion |
|
|
| Recruiting | 1 | 20 | RoW | hAESCs | Second Affiliated Hospital, School of Medicine, Zhejiang University, Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China | Intrauterine Adhesion | 09/22 | 09/23 | | |
NCT05438394: Clinical Study of Safety and Tolerability of Melphalan Hydrochloride for R/R MM |
|
|
| Recruiting | 1 | 24 | RoW | melphalan hydrochloride for injection | Peking University People's Hospital, CASI Pharmaceuticals, Inc. | Multiple Myeloma | 12/23 | 12/23 | | |
AK104-IIT-C-N1-0042, NCT05856864: Cadonilimab in Combination With Ramucirumab for the Treatment of Advanced Hepatocellular Carcinoma That Has Failed at Systemic Therapy |
|
|
| Recruiting | 1 | 30 | RoW | Cadonilimab Injection, AK104, Ramucirumab Injection | Tianjin Medical University Cancer Institute and Hospital | Advanced Hepatocellular Carcinoma That Has Failed at Systemic Therapy | 07/24 | 05/25 | | |
NCT06464965: Clinical Study of Cord Blood-Derived CAR-NK Cells in Gastric Cancer and Pancreatic Cancer |
|
|
| Recruiting | 1 | 30 | RoW | CB CAR-NK182 | Zhejiang Provincial People's Hospital, Zhejiang University, Hangzhou RongGu Biotechnology Limited Company | Gastric Cancer, Pancreas Adenocarcinoma | 06/25 | 06/27 | | |
NCT06528249: Safety, Tolerability and Preliminary Efficacy of Erythrocyte-αPD-1 Conjugate in Patients With Advanced Malignancies |
|
|
| Not yet recruiting | 1 | 39 | NA | Engineered erythrocytes (or red blood cells) covalently conjugated with commercially available anti-PD-1 antibodies on their membranes | Zhejiang Provincial People's Hospital, Westlake Therapeutics | Cancer, Solid Tumor, Hematologic Malignancy | 07/26 | 12/26 | | |
NCT04810910: Personalized Neoantigen Vaccine in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy |
|
|
| Recruiting | 1 | 20 | RoW | iNeo-Vac-P01, Neoantigen peptides, GM-CSF, immune adjuvant, granulocyte-macrophage colony stimulating factor | Zhejiang Provincial People's Hospital, Hangzhou Neoantigen Therapeutics Co., Ltd. | Resectable Pancreatic Cancer | 03/25 | 03/25 | | |
NCT05631899: CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors |
|
|
| Recruiting | 1 | 15 | RoW | KRAS-EphA-2-CAR-DC, Abraxane, Abraxane Injectable Product, Cyclophosphamide, Cyclophosphamide for Injection, Anti-PD-1 antibody, PD-1 blocking antibody, Anti-CTLA4 Monoclonal Antibody, Ipilimumab | Chinese PLA General Hospital, Zhejiang University | Solid Tumor, Adult, EphA2 Overexpression, KRAS G12V, KRAS G12C, KRAS G12D | 12/25 | 12/26 | | |
NCT03809390: Effects of Vaginal Seeding on Infants' Body Mass Index and Allergy Risk for Caesarean-delivered Children |
|
|
| Active, not recruiting | N/A | 117 | RoW | Vaginal seeding | Peking University, National Natural Science Foundation of China, Liuyang Maternal and Child Health Care Hospital | Overweight and Obesity, Allergy | 09/21 | 11/22 | | |
NCT05333497: Programmed Flexor-extensor Alternating Electrical Acupiont Stimulation on Limb Functional Reconstruction After Stroke |
|
|
| Completed | N/A | 84 | RoW | the fourth programmed generation of low-frequency acupoint electric stimulation therapy instrument, the fourth generation of low-frequency acupoint electric stimulation therapy instrument, patent No. : ZL201610793646.9 | Yang Liu | Stroke Sequelae, Movement Disorders | 04/22 | 02/23 | | |
NCT05735054: A Novel Technique for Endoscopic Transaxillary Thyroidectomy Comparison |
|
|
| Active, not recruiting | N/A | 300 | RoW | endoscopic thyroidectomy | Second Affiliated Hospital of Xi'an Jiaotong University | Thyroid Diseases | 12/22 | 12/24 | | |
| Recruiting | N/A | 10254 | RoW | | Limeng Chen | Chronic Kidney Diseases, Chronic Kidney Disease-Mineral and Bone Disorder | 12/24 | 12/24 | | |
| Recruiting | N/A | 714 | RoW | ERA | Peking University Third Hospital, RenJi Hospital, Northwest Women's and Children's Hospital, Xi'an, Shaanxi | Infertility, Female, IVF/ICSI | 03/23 | 04/23 | | |
| Recruiting | N/A | 120 | RoW | Transcatheter aortic valve replacement | Genesis Medtech Corporation | Diseases of Aortic Valve, Aortic Regurgitation Disease | 05/23 | 05/24 | | |
NCT05607667: Clinical Trial in China for Aortic Valve Stenosis |
|
|
| Recruiting | N/A | 53 | RoW | Transcatheter aortic valve replacement | Genesis Medtech Corporation | Diseases of Aortic Valve, Aortic Stenosis Disease | 05/23 | 05/23 | | |
NCT06286631: Prediction of Lymph Node Metastasis in Patients With Thyroid Malignancy by a New Scale |
|
|
| Recruiting | N/A | 800 | RoW | | Second Affiliated Hospital of Xi'an Jiaotong University | Papillary Thyroid Cancer | 10/25 | 10/26 | | |
NCT06192979: Optimize First-line Treatment for AL Amyloidosis With t (11; 14) |
|
|
| Recruiting | N/A | 41 | RoW | Daratumumab, Bortezomib, Dexamethasone, Venetoclax | Jin Lu, MD | Amyloidosis; Systemic, AL Amyloidosis | 12/25 | 06/26 | | |
NCT06448897: Development of an Imaging Prediction Model for Pelvic Lymph Node Metastasis of Cervical Cancer Using Artificial Intelligence Techniques. |
|
|
| Recruiting | N/A | 4000 | RoW | | Obstetrics & Gynecology Hospital of Fudan University | Cervical Cancer, Lymph Node Metastasis, Artificial Intelligence | 12/25 | 12/25 | | |
NCT06423547: Risk Warning Model of Postoperative Delirium and Long-term Cognitive Dysfunction in Elderly Patients |
|
|
| Not yet recruiting | N/A | 10000 | NA | no intervention | Xuanwu Hospital, Beijing, Chongqing Institute of Green and Intelligent Technology, Chinese Academy of Sciences | Postoperative Delirium, Postoperative Neurocognitive Disorder, Surgery | 12/27 | 12/27 | | |
NCT06369935: A Real World Study of Equecabtagene Autoleucel in Subjects With Relapsed and Refractory Multiple Myeloma. |
|
|
| Not yet recruiting | N/A | 260 | RoW | Equecabtagene Autoleucel, CT103A | Peking University People's Hospital | Relapsed/Refractory Multiple Myeloma | 08/26 | 08/27 | | |
NCT06699394: Prospective Study of Teclistamab in the Treatment of Systemic AL Amyloidosis |
|
|
| Recruiting | N/A | 20 | RoW | Teclistamab (Tec) | Peking University People's Hospital | AL Amyloidosis | 12/25 | 12/26 | | |
NCT06697483: Risk Stratification and MRD-driven Maintenance for MM After ASCT |
|
|
| Recruiting | N/A | 100 | RoW | Daratumumab, Lenalidomide | Peking University People's Hospital | Multiple Myeloma | 12/26 | 12/27 | | |
